Given a pdf content file `benchmark/dataset/CovPDB/pdf_content.md`. 

Determining the covalent bonding mechanisms based on the given paper. 

The mechanisms must be one of: Aziridine Opening; Beta-Lactam Addition; Borylation; Composite Reaction; Cyclohemiaminoacetalization; Disulfide Formation; Epoxide Opening; Hemiaminalization; Hemi(thio)acetalization; Imidazolidinone Opening; Imine Condensation; Lactone Addition; Michael Addition; Nucleophilic Acyl Substitution; Nucleophilic Addition to a Double Bond; Nucleophilic Addition to a Triple Bond; Nucleophilic Aliphatic Subsititution; Nucleophilic Aromatic Substitution; Phosphorylation; Ring Opening; Sulfonylation

Saving the mechanisms into `/root/autodl-tmp/biomni_v20260208_pred_results/kimi-k2.5/covpdb_annotate.txt`.  

# Output Format (For Reference)
Sulfonylation

# Intermediate Results
All intermediate files generated should be saved in the directly `/root/autodl-tmp/biomni_v20260208_tmp/kimi-k2.5/covpdb_annotate`

Let me create a plan to solve this task:

1. [ ] Read the PDF content file from `benchmark/dataset/CovPDB/pdf_content.md`
2. [ ] Analyze the content to identify covalent bonding mechanisms
3. [ ] Map the identified mechanism to one of the specified categories
4. [ ] Create the output directory if it doesn't exist
5. [ ] Save the mechanism to the specified output file

Let me start by reading the PDF content file:

<execute>
# Step 1: Read the PDF content file
pdf_content_path = "benchmark/dataset/CovPDB/pdf_content.md"

with open(pdf_content_path, 'r', encoding='utf-8') as f:
    content = f.read()

print("=== PDF Content Preview ===")
print(content[:3000])
print("\n... (content continues)")
print(f"\nTotal length: {len(content)} characters")
</execute>
<observation>=== PDF Content Preview ===
# Manno-epi-cyclophellitols Enable Activity-Based Protein Profiling of Human  \(\alpha\) -Mannosidases and Discovery of New Golgi Mannosidase II Inhibitors

Zachary Armstrong, Chi- Lin Kuo, Daniel Lahav, Bing Liu, Rachel Johnson, Thomas J. M. Beenakker, Casper de Boer, Chung- Sing Wong, Erwin R. van Rijssel, Marjoke F. Debets, Bogdan I. Florea, Colin Hissink, Rolf G. Boot, Paul P. Geurink, Huib Ovaa, Mario van der Stelt, Gijsbert M. van der Marel, Jeroen D. C. Codee, Johannes M. F. G. Aerts, Liang Wu, Herman S. Overkleeft,* and Gideon J. Davies*

Cite This: J. Am. Chem. Soc. 2020, 142, 13021- 13029

![](images/827bed8d6f7bbdd60e8143439fd882cb608be4cff474c080f9a1b447a700198e.jpg)

Read Online

ACCESS

Metrics & More

Article Recommendations

Supporting Information

ABSTRACT: Golgi mannosidase II (GMII) catalyzes the sequential hydrolysis of two mannosyl residues from  \(\mathrm{GlcNAc}\) \(\mathrm{Man}_5\mathrm{GlcNAc}_2\)  to produce  \(\mathrm{GlcNAcMan}_3\mathrm{GlcNAc}_2,\)  the precursor for all complex  \(N\cdot\)  glycans, including the branched  \(N\cdot\)  glycans associated with cancer. Inhibitors of GMII are potential cancer therapeutics, but their usefulness is limited by off- target effects, which produce  \(\alpha\)  - mannosidosis- like symptoms. Despite many structural and mechanistic studies of GMII, we still lack a potent and selective inhibitor of this enzyme. Here, we synthesized manno- epicyclophellitol epoxide and aziridines and demonstrate their covalent modification and time- dependent inhibition of GMII. Application of fluorescent manno- epi- cyclophellitol aziridine derivatives enabled activity- based protein profiling of  \(\alpha\)  - mannosidases from both human cell lysate and mouse tissue extracts. Synthesized probes also facilitated a fluorescence polarization- based screen for dGMII inhibitors. We identified seven previously unknown inhibitors of GMII from a library of over 350 iminosugars and investigated their binding modalities through X- ray crystallography. Our results reveal previously unobserved inhibitor binding modes and promising scaffolds for the generation of selective GMII inhibitors.

![](images/13699143d22cdcc32100b6909544c234052b4ce3e2cefeb35e442afc35773792.jpg)

## INTRODUCTION

Golgi  \(\alpha\)  - mannosidase (GMII, MAN2A1, mannosyl- oligosaccharide  \(1,3 / 1,6 - \alpha\)  - mannosidase) is a glycoside hydrolase from CAZy family  \(\mathrm{GH38^1}\)  that catalyzes sequential hydrolysis of both the terminal  \(\alpha - 1,3\cdot\)  and 1,6- linked mannoses from the  \(N\cdot\)  glycan  \(\mathrm{GlcNAcMan}_5\mathrm{GlcNAc}_2\)  Figure 1A), which is a committed step in the formation of complex  \(N\cdot\)  glycans.2 Altered  \(N\cdot\)  glycan branching has been directly linked to the metastatic potential of cells,4 and consequently, inhibitors of GMII are a potential target for anticancer therapeutics. The potent GMII mannosidase inhibitor swainsonine (Figure 1B), first identified in locoweed, ha

... (content continues)

Total length: 49086 characters
</observation>
Let me search for more specific information about the covalent bonding mechanism in the content:

<execute>
# Step 2: Search for covalent bonding mechanism keywords
keywords = ['epoxide', 'aziridine', 'covalent', 'mechanism', 'inhibition', 'nucleophilic', 'ring opening', 'opening']

for keyword in keywords:
    idx = content.lower().find(keyword)
    if idx != -1:
        # Find context around the keyword
        start = max(0, idx - 200)
        end = min(len(content), idx + 200)
        print(f"\n=== '{keyword.upper()}' found at position {idx} ===")
        print(content[start:end])
        print("="*50)
</execute>
<observation>NameError("name 'content' is not defined")</observation>
<execute>
# Re-read the PDF content and search for mechanism
pdf_content_path = "benchmark/dataset/CovPDB/pdf_content.md"

with open(pdf_content_path, 'r', encoding='utf-8') as f:
    content = f.read()

# Search for key terms related to covalent bonding mechanism
keywords = ['epoxide', 'aziridine', 'covalent', 'mechanism', 'ring opening', 'inhibition', 'nucleophilic']

for keyword in keywords:
    count = content.lower().count(keyword)
    print(f"'{keyword}': {count} occurrences")

# Look for the mechanism description
print("\n" + "="*60)
print("Searching for mechanism descriptions:")
print("="*60)

# Find sections describing the mechanism
lines = content.split('\n')
for i, line in enumerate(lines):
    if 'epoxide' in line.lower() or 'aziridine' in line.lower():
        if i > 0:
            print(f"\nLine {i}: {line.strip()}")
            if i+1 < len(lines):
                print(f"Line {i+1}: {lines[i+1].strip()}")
</execute>
<observation>'epoxide': 5 occurrences
'aziridine': 15 occurrences
'covalent': 12 occurrences
'mechanism': 6 occurrences
'ring opening': 0 occurrences
'inhibition': 33 occurrences
'nucleophilic': 1 occurrences

============================================================
Searching for mechanism descriptions:
============================================================

Line 18: ABSTRACT: Golgi mannosidase II (GMII) catalyzes the sequential hydrolysis of two mannosyl residues from  \(\mathrm{GlcNAc}\) \(\mathrm{Man}_5\mathrm{GlcNAc}_2\)  to produce  \(\mathrm{GlcNAcMan}_3\mathrm{GlcNAc}_2,\)  the precursor for all complex  \(N\cdot\)  glycans, including the branched  \(N\cdot\)  glycans associated with cancer. Inhibitors of GMII are potential cancer therapeutics, but their usefulness is limited by off- target effects, which produce  \(\alpha\)  - mannosidosis- like symptoms. Despite many structural and mechanistic studies of GMII, we still lack a potent and selective inhibitor of this enzyme. Here, we synthesized manno- epicyclophellitol epoxide and aziridines and demonstrate their covalent modification and time- dependent inhibition of GMII. Application of fluorescent manno- epi- cyclophellitol aziridine derivatives enabled activity- based protein profiling of  \(\alpha\)  - mannosidases from both human cell lysate and mouse tissue extracts. Synthesized probes also facilitated a fluorescence polarization- based screen for dGMII inhibitors. We identified seven previously unknown inhibitors of GMII from a library of over 350 iminosugars and investigated their binding modalities through X- ray crystallography. Our results reveal previously unobserved inhibitor binding modes and promising scaffolds for the generation of selective GMII inhibitors.
Line 19: 

Line 33: In the pursuit of new inhibitors of GMII we have applied the considerable power of cyclophellitol- like activity- based probes (ABPs).  \({ }^{20}\)  Herein we report the covalent inhibition of GMII with manno- epi- cyclophellitol epoxide and aziridine. A fluorescent derivative of the manno- epi- cyclophellitol aziridine enabled activity- based protein profiling (ABPP) of GH38  \(\alpha\) - mannosidases in both cells overexpressing human GH38s and mouse tissue extracts. This labeling could be reduced with known inhibitors of GH38s. We next developed a high- throughput fluorescence polarization ABPP screen for  \(\alpha\) - mannosidase inhibitors. Screening of our in- house focused library of over 350 iminosugars revealed seven previously unidentified GMII inhibitors, some of which were found by X- ray crystallography to bind in modes distinct from previously observed inhibitors. Together this gives us fresh insight into the design of GMII inhibitors and lead compounds for the creation of second- generation GMII inhibitors while also providing a high- throughput screening protocol for future library assessment.
Line 34: 

Line 39: Both the manno- epi- cyclophellitol epoxide (1) and aziridine (2) were synthesized (see Figure 2 and the Supporting
Line 40: 

Line 44: Information for synthetic details) to ascertain whether these inhibitors could target dGMII. When 1 and 2 were incubated with recombinant dGMII, we observed that both displayed time- dependent inhibition, which is typical for cyclophellitol- type inhibitors (see Figure S1). To compare the reactivity of these two compounds, second- order rate constants  \(\left(k_{\text{inact}} / K_{\text{I}}\right)\)  were determined using 4- methylumbelliferyl  \(\alpha\) - D- mannopyranoside (MU-  \(\alpha\) - Man) as a substrate. The  \(k_{\text{inact}} / K_{\text{I}}\)  value for 1 was determined to be  \(50 \pm 5 \mathrm{min}^{- 1} \mathrm{M}^{- 1}\) , while the observed inhibition constant for aziridine 2 was over 100- fold higher  \(\left(5500 \pm 100 \mathrm{min}^{- 1} \mathrm{M}^{- 1}\right)\) . This enhanced inhibition of 2 is consistent with the trend previously observed for  \(\alpha\) - glucosidases by epi- cyclophellitol epoxides and aziridines.  \({ }^{26}\)
Line 45: 

Line 46: We next obtained a crystal structure of dGMII that had been soaked with aziridine 2. The reacted manno- epi- cyclophellitol moiety is covalently linked to the nucleophile Asp204 in the X- ray structure (Figure 3B). This structure clearly shows the opening of the aziridine ring resulting from nucleophilic attack at the pseudoanomeric carbon (Figure 3A). The resulting enzyme- bound cyclitol structure displays a  \({ }^{1} \mathrm{~S}_{5}\)  skew boat conformation, which is consistent with the proposed  \({ }^{0} \mathrm{~S}_{2} / \mathrm{B}_{2,5} \rightarrow \mathrm{B}_{2,5}{}_{2}^{+} \rightarrow {}^{1} \mathrm{~S}_{5}\)  reaction itinerary for GH38  \(\alpha\) - mannosidases.  \({ }^{21,27}\)  Comparison to the structure of 2- deoxy- 2- fluoro- D- mannose bound to the dGMII D341N acid/base mutant  \({ }^{21}\)
Line 47: 

Line 49: Figure 3. Covalent inhibition of dGMII with manno-epi-cyclophellitol aziridine. (A) Mechanism of covalent inhibition of  \(\alpha\) -mannosidase by manno-epi-cyclophellitols. (B) Structure of 2 covalently linked to dGMII. The  \(2F_{0} - F_{c}\)  map is contoured at  \(1.5\sigma\) ,  \((0.48~\mathrm{e}^{-} / \mathrm{\AA}^{3})\) . (C) Overlay of 2 covalently bound to dGMII and 2-deoxy-2-fluoro-b-mannose bound to the D341N variant of dGMII (PDB: 1QX1). The bound (and reacted) manno-epi-cyclophellitol aziridine is shown in green, while the bound 2-fluoromannose is shown in blue.
Line 50: 

Line 55: Manno- epi- cyclophellitol Aziridine Probes React with All Human GH38  \(\alpha\) - Mannosidases. To determine whether human mannosidases would react with the cyclophellitol aziridine probes within complex mixtures, all five human GH38  \(\alpha\) - mannosidases (epididylmis- specific  \(\alpha\) - mannosidase (hEpman), hGMII, hLAM, hMan2A2, and hMan2C1) were individually cloned and expressed in HEK293T cells, and extracts thereof treated with  \(3\mu \mathrm{M}\)  ABP 4 in buffers with  \(\mathrm{pH}\)  between 4 and 7.5 for  \(30\mathrm{min}\)  at  \(37^{\circ}C\) . All five human GH38s could be detected by in- gel fluorescence scanning of gels containing SDS- PAGE- separated proteins with intensities greater than that seen for a mock (no transfection) control. In addition, each of the five cloned enzymes proved to react with the probe in a  \(\mathrm{pH}\) - dependent manner. Lysates of cells transfected with the Golgi- resident hGMII and hMan2A2 and treated with 4 gave similar labeling patterns with bands at approximately  \(140\mathrm{kDa}\)  and maximal read- out at  \(\mathrm{pH}5.5 - 6.0\)
Line 56: 

Line 122: Manno- epi- cyclophellitols have proven to be powerful tools for the study of GH38  \(\alpha\)  - mannosidases and the identification of new inhibitors. The epoxide and aziridine analogues and fluorescent derivatives are covalent time- dependent inhibitors. X- ray crystallography has revealed the  \({}^{1}S_{5}\)  conformation of these cyclophellitols, which is consistent with theoretical predictions for the glycosyl- enzyme intermediate. Fluorescent derivatives have enabled the profiling of tissue- dependent GH38 activity and a previously unseen proteolyzed form of hEpman. Additionally, a FluoPol- ABPP screen with excellent characteristics and low substrate and enzyme requirements was developed using the fluorescently tagged manno- epi- cyclophellitol aziridine. This screen revealed seven new inhibitors of both dGMII and hGMII, including D- lyxo- configured pyrrolidines, deoxynojirimycins, hydroxylated piperidines, and an alkylated glucoinidazole. X- ray crystallography of these compounds bound to dGMII revealed both new binding modes and potential sites for inhibitor diversification. This work sets the stage for future development of selective GMII inhibitors. Furthermore, the low material cost in terms of both enzyme and substrate of the screen developed herein will enable the screening of  \(\alpha\)  - mannosidases, which may only be expressed in small quantities. This in turn should enable the screening for inhibitors of all human  \(\alpha\)  - mannosidases.
Line 123: 
</observation>
Let me search for more specific mechanistic details to confirm:

<execute>
# Step 3: Look for detailed mechanistic descriptions
print("="*60)
print("Detailed Mechanism Analysis:")
print("="*60)

# Find the specific mechanism section
import re

# Search for mechanism-related content
mechanism_matches = []
for i, line in enumerate(lines):
    if 'mechanism' in line.lower() or 'opening' in line.lower():
        mechanism_matches.append((i, line.strip()))

print("\nMechanism-related lines:")
for idx, (line_num, line) in enumerate(mechanism_matches[:20]):
    print(f"Line {line_num}: {line}")

# Look for Figure 3 which describes the mechanism
print("\n" + "="*60)
print("Looking for Figure 3 description:")
print("="*60)

for i, line in enumerate(lines):
    if 'Figure 3' in line or 'mechanism of covalent inhibition' in line.lower():
        for j in range(max(0, i-2), min(len(lines), i+5)):
            print(f"Line {j}: {lines[j].strip()}")
</execute>
<observation>NameError("name 'lines' is not defined")</observation>
<execute>
# Re-read and analyze mechanism details
pdf_content_path = "benchmark/dataset/CovPDB/pdf_content.md"

with open(pdf_content_path, 'r', encoding='utf-8') as f:
    content = f.read()

lines = content.split('\n')

# Search for mechanism-related content
print("="*60)
print("Mechanism-related lines:")
print("="*60)

for i, line in enumerate(lines):
    if 'mechanism' in line.lower() or 'ring opening' in line.lower() or 'nucleophilic attack' in line.lower():
        print(f"Line {i}: {line.strip()}")

print("\n" + "="*60)
print("Looking for Figure 3 - Mechanism description:")
print("="*60)

for i, line in enumerate(lines):
    if 'Figure 3' in line or 'Figure 3.' in line or 'mechanism of covalent inhibition' in line.lower():
        for j in range(max(0, i-1), min(len(lines), i+6)):
            if j < len(lines):
                print(f"Line {j}: {lines[j].strip()}")
</execute>
<observation>The output is too long to be added to context. Here are the first 10K characters...
============================================================
Mechanism-related lines:
============================================================
Line 37: Manno- epi- cyclophellitols Are Time- Dependent Inhibitors of dGMII. GMII is a GH38 retaining  \(\alpha\) - D- mannosidase that employs a two- step, double- displacement mechanism in which a covalent- enzyme intermediate is flanked by oxocarbenium- ion- like transition states.  \({ }^{21}\)  We reasoned that as the GH38 mechanism processes through a covalent intermediate, GMII would be an ideal target for the cyclophellitol class of GH inhibitors, which have become a powerful scaffold for the creation of activity- based glycosidase probes.  \({ }^{20}\)  The cyclophellitol class of GH inhibitors covalently modify retaining GHs, and activity- based probes bearing cyclophellitol warheads have enabled high- throughput inhibitor and drug discovery,  \({ }^{22}\)  biomass enzyme profiling,  \({ }^{23}\)  and detailed conformational and structural insight.  \({ }^{24,25}\)
Line 46: We next obtained a crystal structure of dGMII that had been soaked with aziridine 2. The reacted manno- epi- cyclophellitol moiety is covalently linked to the nucleophile Asp204 in the X- ray structure (Figure 3B). This structure clearly shows the opening of the aziridine ring resulting from nucleophilic attack at the pseudoanomeric carbon (Figure 3A). The resulting enzyme- bound cyclitol structure displays a  \({ }^{1} \mathrm{~S}_{5}\)  skew boat conformation, which is consistent with the proposed  \({ }^{0} \mathrm{~S}_{2} / \mathrm{B}_{2,5} \rightarrow \mathrm{B}_{2,5}{}_{2}^{+} \rightarrow {}^{1} \mathrm{~S}_{5}\)  reaction itinerary for GH38  \(\alpha\) - mannosidases.  \({ }^{21,27}\)  Comparison to the structure of 2- deoxy- 2- fluoro- D- mannose bound to the dGMII D341N acid/base mutant  \({ }^{21}\)
Line 49: Figure 3. Covalent inhibition of dGMII with manno-epi-cyclophellitol aziridine. (A) Mechanism of covalent inhibition of  \(\alpha\) -mannosidase by manno-epi-cyclophellitols. (B) Structure of 2 covalently linked to dGMII. The  \(2F_{0} - F_{c}\)  map is contoured at  \(1.5\sigma\) ,  \((0.48~\mathrm{e}^{-} / \mathrm{\AA}^{3})\) . (C) Overlay of 2 covalently bound to dGMII and 2-deoxy-2-fluoro-b-mannose bound to the D341N variant of dGMII (PDB: 1QX1). The bound (and reacted) manno-epi-cyclophellitol aziridine is shown in green, while the bound 2-fluoromannose is shown in blue.
Line 168: (21) Numao, S.; Kuntz, D. A.; Withers, S. G.; Rose, D. R. Insights into the Mechanism of Drosophila melanogaster Golgi  \(\alpha\) -Mannosidase II through the Structural Analysis of Covalent Reaction Intermediates. J. Biol. Chem. 2003, 278 (48), 48074-48083.
Line 174: (27) Petersen, L.; Ard√®vol, A.; Rovira, C.; Reilly, P. J. Molecular Mechanism of the Glycosylation Step Catalyzed by Golgi  \(\alpha\) -Mannosidase II: A QM/MM Metadynamics Investigation. J. Am. Chem. Soc. 2010, 132 (24), 8291-8300.
Line 180: Man2a2 in the mouse. Biochim. Biophys. Acta, Gen. Subj. 2002, 1573 (3), 382- 387.  (32) Hiramoto, S.; Tamba, M.; Kiuchi, S.; Jin, Y.- Z.; Bannai, S.; Sugita, Y.; Dacheux, F.; Dacheux, J.- L.; Yoshida, M.; Okamura, N. Stage- Specific Expression of a Mouse Homologue of the Porcine 135 kDa  \(\alpha\) - D- Mannosidase (MAN2B2) in Type A Spermatogonia. Biochem. Biophys. Res. Commun. 1997, 241 (2), 439- 445.  (33) Costanzi, E.; Balducci, C.; Cacan, R.; Duvet, S.; Orlacchio, A.; Beccari, T. Cloning and expression of mouse cytosolic  \(\alpha\) - mannosidase (Man2c1). Biochim. Biophys. Acta, Gen. Subj. 2006, 1760 (10), 1580- 1586.  (34) Bachovchin, D. A.; Brown, S. J.; Rosen, H.; Cravatt, B. F. Identification of selective inhibitors of uncharacterized enzymes by high- throughput screening with fluorescent activity- based probes. Nat. Biotechnol. 2009, 27 (4), 387- 394.  (35) Lea, W. A.; Simeonov, A. Fluorescence polarization assays in small molecule screening. Expert Opin. Drug Discovery 2011, 6 (1), 17- 32.  (36) Rabouille, C.; Kuntz, D. A.; Lockyer, A.; Watson, R.; Signorelli, T.; Rose, D. R.; van den Heuvel, M.; Roberts, D. B. The Drosophila GMII gene encodes a Golgi  \(\alpha\) - mannosidase II. J. Cell Sci. 1999, 112, 3319- 3330.  (37) Kuntz, D. A.; Zhong, W.; Guo, J.; Rose, D. R.; Boons, G.- J. The Molecular Basis of Inhibition of Golgi  \(\alpha\) - Mannosidase II by Mannostatin A. ChemBioChem 2009, 10 (2), 268- 277.  (38) Zhang, J. H. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J. Biomol. Screening 1999, 4 (2), 67- 73.  (39) van den Elsen, J. M. H. Structure of Golgi  \(\alpha\) - mannosidase II: a target for inhibition of growth and metastasis of cancer cells. EMBO Journal 2001, 20 (12), 3008- 3017.  (40) Englebienne, P.; Fiaux, H.; Kuntz, D. A.; Corbeil, C. R.; Gerber- Lemaire, S.; Rose, D. R.; Moitesier, N. Evaluation of docking programs for predicting binding of Golgi  \(\alpha\) - mannosidase II inhibitors: A comparison with crystallography. Proteins: Struct., Funct., Genet. 2007, 69 (1), 160- 176.  (41) Kuntz, D. A.; Liu, H.; Bols, M.; Rose, D. R. The role of the active site Zn in the catalytic mechanism of the GH38 Golgi  \(\alpha\) - mannosidase II: Implications from noethromycin inhibition. Biocatal. Biotransform. 2006, 24 (1- 2), 55- 61.

============================================================
Looking for Figure 3 - Mechanism description:
============================================================
Line 45: 
Line 46: We next obtained a crystal structure of dGMII that had been soaked with aziridine 2. The reacted manno- epi- cyclophellitol moiety is covalently linked to the nucleophile Asp204 in the X- ray structure (Figure 3B). This structure clearly shows the opening of the aziridine ring resulting from nucleophilic attack at the pseudoanomeric carbon (Figure 3A). The resulting enzyme- bound cyclitol structure displays a  \({ }^{1} \mathrm{~S}_{5}\)  skew boat conformation, which is consistent with the proposed  \({ }^{0} \mathrm{~S}_{2} / \mathrm{B}_{2,5} \rightarrow \mathrm{B}_{2,5}{}_{2}^{+} \rightarrow {}^{1} \mathrm{~S}_{5}\)  reaction itinerary for GH38  \(\alpha\) - mannosidases.  \({ }^{21,27}\)  Comparison to the structure of 2- deoxy- 2- fluoro- D- mannose bound to the dGMII D341N acid/base mutant  \({ }^{21}\)
Line 47: 
Line 48: ![](images/e199f9541834e2daea09e432f6c1a6fd8d570a2bdafeefa181d410465c226ed4.jpg)
Line 49: Figure 3. Covalent inhibition of dGMII with manno-epi-cyclophellitol aziridine. (A) Mechanism of covalent inhibition of  \(\alpha\) -mannosidase by manno-epi-cyclophellitols. (B) Structure of 2 covalently linked to dGMII. The  \(2F_{0} - F_{c}\)  map is contoured at  \(1.5\sigma\) ,  \((0.48~\mathrm{e}^{-} / \mathrm{\AA}^{3})\) . (C) Overlay of 2 covalently bound to dGMII and 2-deoxy-2-fluoro-b-mannose bound to the D341N variant of dGMII (PDB: 1QX1). The bound (and reacted) manno-epi-cyclophellitol aziridine is shown in green, while the bound 2-fluoromannose is shown in blue.
Line 50: 
Line 51: (PDB ID: 1QX1) revealed excellent concordance with the bound 2- fluorosugar- enzyme intermediate (Figure 3C).
Line 48: ![](images/e199f9541834e2daea09e432f6c1a6fd8d570a2bdafeefa181d410465c226ed4.jpg)
Line 49: Figure 3. Covalent inhibition of dGMII with manno-epi-cyclophellitol aziridine. (A) Mechanism of covalent inhibition of  \(\alpha\) -mannosidase by manno-epi-cyclophellitols. (B) Structure of 2 covalently linked to dGMII. The  \(2F_{0} - F_{c}\)  map is contoured at  \(1.5\sigma\) ,  \((0.48~\mathrm{e}^{-} / \mathrm{\AA}^{3})\) . (C) Overlay of 2 covalently bound to dGMII and 2-deoxy-2-fluoro-b-mannose bound to the D341N variant of dGMII (PDB: 1QX1). The bound (and reacted) manno-epi-cyclophellitol aziridine is shown in green, while the bound 2-fluoromannose is shown in blue.
Line 50: 
Line 51: (PDB ID: 1QX1) revealed excellent concordance with the bound 2- fluorosugar- enzyme intermediate (Figure 3C).
Line 52: 
Line 53: The rapid time- dependent inactivation of dGMII by 2 and the orientation of the amine toward the solvent suggested that this inhibitor could serve as the scaffold for the design of activity- based probes. Toward the goal of designing ABPs we synthesized azido-  \(n\) - octyl manno- epi- cyclophellitol (3, Figure 2) starting from D- ribose in 15 steps and used a copper(I)- catalyzed azide- alkyne [2- 3] cycloaddition to ligate this to either Cy5- alkyne, biotin- alkyne, or  \(5^{\prime} / 6^{\prime}\) - TAMRA-  \(\mathrm{PEG}_4\) - alkyne to yield ABPs 4, 5, and 6, respectively. Detailed synthetic procedures are given in the Supporting Information.
Line 54: 
Line 50: 
Line 51: (PDB ID: 1QX1) revealed excellent concordance with the bound 2- fluorosugar- enzyme intermediate (Figure 3C).
Line 52: 
Line 53: The rapid time- dependent inactivation of dGMII by 2 and the orientation of the amine toward the solvent suggested that this inhibitor could serve as the scaffold for the design of activity- based probes. Toward the goal of designing ABPs we synthesized azido-  \(n\) - octyl manno- epi- cyclophellitol (3, Figure 2) starting from D- ribose in 15 steps and used a copper(I)- catalyzed azide- alkyne [2- 3] cycloaddition to ligate this to either Cy5- alkyne, biotin- alkyne, or  \(5^{\prime} / 6^{\prime}\) - TAMRA-  \(\mathrm{PEG}_4\) - alkyne to yield ABPs 4, 5, and 6, respectively. Detailed synthetic procedures are given in the Supporting Information.
Line 54: 
Line 55: Manno- epi- cyclophellitol Aziridine Probes React with All Human GH38  \(\alpha\) - Mannosidases. To determine whether human mannosidases would react with the cyclophellitol aziridine probes within complex mixtures, all five human GH38  \(\alpha\) - mannosidases (epididylmis- specific  \(\alpha\) - mannosidase (hEpman), hGMII, hLAM, hMan2A2, and hMan2C1) were individually cloned and expressed in HEK293T cells, and extracts thereof treated with  \(3\mu \mathrm{M}\)  ABP 4 in buffers with  \(\mathrm{pH}\)  between 4 a</observation>
Based on my analysis of the PDF content, I've identified the covalent bonding mechanism:

**Key findings:**
1. The paper describes "manno-epi-cyclophellitol epoxide and aziridines" as covalent inhibitors
2. Line 46 clearly states: "This structure clearly shows the opening of the aziridine ring resulting from nucleophilic attack at the pseudoanomeric carbon"
3. The mechanism involves aziridine ring opening by nucleophilic attack from Asp204 (the enzyme's nucleophile)

This mechanism maps to **"Aziridine Opening"** from the provided list.

Let me create the output directory and save the result:

<execute>
import os

# Step 4: Create output directory
output_dir = "/root/autodl-tmp/biomni_v20260208_tmp/kimi-k2.5/covpdb_annotate"
os.makedirs(output_dir, exist_ok=True)
print(f"Created directory: {output_dir}")

# Step 5: Save the mechanism to the output file
mechanism = "Aziridine Opening"
output_file = "/root/autodl-tmp/biomni_v20260208_pred_results/kimi-k2.5/covpdb_annotate.txt"

# Create parent directory if needed
os.makedirs(os.path.dirname(output_file), exist_ok=True)

with open(output_file, 'w', encoding='utf-8') as f:
    f.write(mechanism)

print(f"Mechanism saved to: {output_file}")
print(f"Content: {mechanism}")

# Verify
with open(output_file, 'r', encoding='utf-8') as f:
    saved_content = f.read()
print(f"\nVerification - File content: '{saved_content}'")
</execute>
<observation>Created directory: /root/autodl-tmp/biomni_v20260208_tmp/kimi-k2.5/covpdb_annotate
Mechanism saved to: /root/autodl-tmp/biomni_v20260208_pred_results/kimi-k2.5/covpdb_annotate.txt
Content: Aziridine Opening

Verification - File content: 'Aziridine Opening'
</observation>
<solution>
Aziridine Opening
</solution>